Effectiveness and safety of once-weekly semaglutide: findings from the SEMACOL-REAL retrospective multicentric observational study in Colombia.

What moved togetherboth groups pooled, not the treatment’s effect

Correlation, not cause

−1.47percentage points−1.76 to −1.17

As reported

difference −1.47 %, 95% CI −1.76 to −1.17

Correlation, not cause

−4.23kg−5.34 to −3.12

As reported

difference −4.23 kg, 95% CI −5.34 to −3.12

the abstract, start to end

… with a mean reduction in HbA1C of -1.47% (95% CI -1.76, -1.17), weight loss of -4.23 kg (95% CI -5.34, -3.12), and …

← favours treatmentfavours comparator →

could be chance

Kidney outcomes

−1.47−1.76 to −1.17

Glycemic control

−4.23−5.34 to −3.12

GLP-1 receptor agonistsGlycemic controlKidney outcomes

1 / 3